Why I think FTSE 100 medical tech stock Smith & Nephew looks a good investment

I like the investment case for FTSE 100 medical tech stock Smith & Nephew. It’s been hammered by the pandemic but I think the future looks promising.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 medical technology stock Smith & Nephew (LSE:SN) is an international brand that’s been around for 165 years. While some healthcare stocks have thrived during the pandemic, Smith & Nephew has struggled. It provides replacement prosthetic hips and knees for operations. And with most elective surgery postponed or cancelled recently, the company has lost orders and reduced its revenue.

Short-term struggles

Nevertheless, when considering the bigger picture, I think it’s easy to see that this is a short-term problem. I believe surgery is going to return with a vengeance and the FTSE 100 company will pick up again. With the NHS facing a massive backlog (around five years waiting time for a knee or hip replacement), I think more and more patients will opt for private surgery.

Its full-year 2020 results released last week were disappointing, causing the stock to fall 5% and making it the worst performer in the FTSE 100 index. In Q4, Smith & Nephew’s revenue fell 7% on an underlying basis. Full-year revenue for 2020 was $4.5bn, an underlying drop of 12%. Its trading profit margin was 15%, which was affected by lower gross margins, increased research and development and general costs. Meanwhile, cash generated from operations fell 29%.

Although further lockdowns were disappointing for Q4, the slowdown was less severe than in Q2. That’s because it was less of a shock and the healthcare system had adapted to manage a lower level of elective surgeries while maintaining Covid-19 safe practice.

There’s strength in the FTSE 100

The good news is, it’s still paying a dividend, making acquisitions and investing in R&D. And in the year ahead, its focus is on recapturing its pre-pandemic momentum. Recovery is likely to be slow in the first half of this year. But hopefully this will pick up pace going into 2022.

Smith & Nephew has launched its CORI robotics system to a positive response. It’s also enjoying vigorous growth in Sports Medicine Joint Repair with its REGENETEN Bioinductive Implant for tendon repair. This product and another called NOVOSTITCH are doing well in the US and have yet to roll out in other markets, meaning potential for increased revenues is present across the company portfolio.

In January it completed its $240m acquisition of Extremity Orthopaedics business of Integra LifeSciences Holdings. This comes a year after its Tusker Medical acquisition. This division operates Tula, an innovative system to treat recurrent or persistent ear infections, particularly in children.

Smith & Nephew’s financial position

The company has a £12.5bn market cap. It has a price-to-earnings ratio (P/E) of 39, and earnings per share are 36p. With a strong balance sheet, the company felt confident in maintaining its progressive dividend policy. Its full-year distribution is 37.5¢ (27p) per share, which gives a yield of 1.9%.

Smith & Nephew has access to committed debt facilities of $4.5bn for around five years. Debt due this year amounts to $265m.

The high P/E shows many shareholders already feel bullish towards this stock. I feel that way too and would like to own shares in Smith & Nephew. Recovery could be slow, there’s a road map out of the pandemic, but no guarantees on the timeline. As a long-term investment, I think this FTSE 100 stalwart has what it takes to go the distance. I imagine when Smith & Nephew’s share price recovery comes, it will be swift, and I’d like to be a shareholder before that happens.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »